Financial Performance - For the nine months ended December 31, 2019, the company reported a total revenue of HKD 38,562,000, a slight increase from HKD 38,591,000 in the same period of 2018[5] - The company incurred a loss of HKD 2,154,000 for the nine months ended December 31, 2019, compared to a loss of HKD 5,796,000 in the same period of 2018, indicating an improvement in performance[5] - Basic and diluted loss per share for the nine months ended December 31, 2019, was HKD 0.19, compared to HKD 0.64 for the same period in 2018[5] - The company reported a total comprehensive loss attributable to owners of the company of HKD 931,000 for the nine months ended December 31, 2019, compared to HKD 1,268,000 in the same period of 2018[5] - The company recorded a loss attributable to owners of approximately HKD 0.9 million for the nine months ended December 31, 2019, a decrease of about 71.0% compared to a loss of approximately HKD 3.1 million for the same period in 2018[48] - The basic loss per share for the nine months ended December 31, 2019, was HKD 0.19, a reduction of approximately 70.3% from HKD 0.64 for the same period in 2018[48] Revenue Breakdown - The company’s revenue is generated from diagnostic services, prescription and dispensing services, and skincare treatments[34] - For the nine months ended December 31, 2019, the total revenue was approximately HKD 38.6 million, with diagnostic services, prescription and dispensing services, and treatment services contributing approximately HKD 1.2 million, HKD 11.8 million, and HKD 25.6 million, respectively, accounting for 3.1%, 30.7%, and 66.2% of total revenue[47] Operating Expenses - Total operating expenses for the nine months ended December 31, 2019, were HKD 7.86 million, down from HKD 16.17 million in the previous year[37] - The company’s employee costs for the nine months ended December 31, 2019, were HKD 18,453,000, compared to HKD 19,044,000 in the same period of 2018, showing a reduction[5] - Other expenses decreased by approximately HKD 8.3 million, or 51.2%, to HKD 7.9 million for the nine months ended December 31, 2019, attributed to reduced rental expenses and marketing costs[60] - The company’s other operating expenses included property rental and related expenses of HKD 1.31 million for the nine months ended December 31, 2019[37] Lease and Asset Management - The company recognized right-of-use assets amounting to HKD 20,390,000 and lease liabilities of HKD 20,022,000 upon the initial application of HKFRS 16 on April 1, 2019[32] - The company applied the short-term lease exemption for leases with a term of 12 months or less and for low-value asset leases, recognizing lease payments as expenses on a straight-line basis[15] - The company measures lease liabilities at the present value of unpaid lease payments, using the incremental borrowing rate if the implicit rate is not readily determinable[22] - The company will adjust lease liabilities and related right-of-use assets if there are changes in lease terms or assessments regarding purchase options[26] Corporate Governance and Shareholding - The audit committee, consisting of three independent non-executive directors, reviewed the unaudited consolidated financial statements for the nine months ended December 31, 2019, ensuring compliance with applicable accounting standards[80] - The company has complied with the corporate governance code as per GEM listing rules during the nine months ended December 31, 2019[73] - Topline holds a beneficial ownership of 274,865,400 shares, representing 56.59% of the issued share capital[69] - 富麒控股有限公司, 富麒, holds 80,000,000 shares, accounting for 16.47% of the issued share capital[69] - Magnolia Wealth International Limited and Mr.季昌群 each hold 80,000,000 shares, also representing 16.47% of the issued share capital[69] Future Outlook - The company will continue to focus on introducing new services and products to maintain competitiveness and explore new business opportunities in response to economic challenges[51]

Financial Performance - For the six months ended September 30, 2019, the company reported total revenue of HKD 25,858,000, an increase of 3.4% compared to HKD 24,994,000 for the same period in 2018[6] - The company incurred a loss of HKD 1,426,000 for the six months ended September 30, 2019, compared to a loss of HKD 5,259,000 for the same period in 2018, representing a 72.9% improvement[6] - Basic and diluted loss per share for the six months ended September 30, 2019, was HKD 0.13, a decrease from HKD 0.63 for the same period in 2018[8] - The total comprehensive loss for the period was HKD 683,000, compared to a total comprehensive loss of HKD 1,490,000 for the previous period[17] - The company recorded a loss of HKD 651,000 during the period, which is an improvement from a loss of HKD 3,012,000 in the same period last year[17] - The group reported total revenue of HKD 25,858,000 for the six months ended September 30, 2019, compared to HKD 24,994,000 for the same period in 2018, representing a year-over-year increase of 3.45%[43] - The group incurred a pre-tax loss of HKD 5,198,000 for the six months ended September 30, 2019, compared to HKD 2,147,000 in the same period of 2018[47] - The group recorded a loss attributable to owners of the company of approximately HKD 0.7 million, a decrease of about 76.7% compared to a loss of approximately HKD 3.0 million for the same period last year[86] Assets and Liabilities - The company's total assets as of September 30, 2019, amounted to HKD 57,394,000, compared to HKD 33,476,000 as of March 31, 2019, indicating a significant increase[11] - The company's cash and cash equivalents increased to HKD 40,257,000 as of September 30, 2019, up from HKD 15,920,000 as of March 31, 2019[11] - The company reported a decrease in total liabilities to HKD 39,253,000 as of September 30, 2019, down from HKD 32,506,000 as of March 31, 2019[13] - The company has a net asset value of HKD 9,559,000 as of September 30, 2019, compared to HKD 55,089,000 as of March 31, 2019[15] - The company's total equity as of September 30, 2019, was HKD 34,341,000, a decrease from HKD 61,088,000 as of March 31, 2018[17] Revenue Breakdown - Revenue from consultation services was HKD 873,000, a decrease of 7.03% from HKD 939,000 in the previous year[44] - Revenue from prescription and dispensing services was HKD 7,753,000, down 9.46% from HKD 8,565,000 in the prior year[44] - Revenue from treatment services increased to HKD 17,232,000, up 11.27% from HKD 15,490,000 in the previous year[44] - Revenue from treatment services accounted for over 50% of total revenue, primarily involving injections of botulinum toxin and hyaluronic acid, as well as laser and radiofrequency treatments[86] Cash Flow and Investments - For the six months ended September 30, 2019, the company reported a net cash generated from operating activities of HKD 8,447,000, a significant increase from HKD 1,081,000 in the same period of 2018[20] - The company generated net cash from investing activities of HKD 38,790,000, a recovery from a net cash outflow of HKD 2,439,000 in the prior year[20] - The company paid dividends amounting to HKD 19,429,000 during the period, compared to HKD 721,000 in the same period last year[20] - The company acquired property, plant, and equipment for approximately HKD 1,618,000 during the six months ended September 30, 2019, compared to HKD 2,668,000 for the same period in 2018, representing a decrease of about 39.25%[57] Corporate Governance and Compliance - The company has adopted the corporate governance code as per GEM Listing Rules Appendix 15 and has complied with it during the reporting period[121] - The audit committee, consisting of three independent non-executive directors, reviewed the unaudited interim financial statements for the six months ending September 30, 2019, and found them compliant with applicable accounting standards[128] - The company’s chairman and CEO roles are held by the same individual, which is a deviation from the corporate governance code, but the board believes this structure enhances business strategy implementation[122] Future Outlook and Strategy - The company plans to focus on expanding its market presence and developing new products in the upcoming quarters[6] - The company plans to continue focusing on developing new services and products to expand market share and explore new business opportunities amid economic challenges[89] - The company is planning to expand its market presence in Southeast Asia, targeting a 25% increase in market share within the next year[130] - A strategic acquisition of a smaller tech firm is in progress, expected to enhance the company's product offerings and increase overall competitiveness in the market[130] - The company has implemented new marketing strategies that have resulted in a 30% increase in customer engagement metrics[130] - The board has approved a budget increase of 15% for marketing efforts to support the upcoming product launches and market expansion initiatives[130] - The company is focusing on sustainability initiatives, with a goal to reduce operational costs by 10% through energy-efficient technologies by the end of the fiscal year[130] Shareholder Information - The board declared a special dividend of HKD 0.04 per share, totaling HKD 19,429,000, which was distributed to shareholders on July 26, 2019[51] - The company did not recommend the payment of an interim dividend for the six months ended September 30, 2019, compared to no interim dividend in 2018[52] - As of September 30, 2019, Topline holds 274,865,400 shares, representing 56.59% of the issued share capital[117] - 富麒控股有限公司 and its controlled entities each hold 80,000,000 shares, accounting for 16.47% of the issued share capital[117] Employee Costs and Operational Efficiency - The company has reported a significant reduction in employee costs, with total employee costs of HKD 12,533,000 for the six months ended September 30, 2019, compared to HKD 12,614,000 for the same period in 2018[6] - Employee costs totaled HKD 12,533,000 for the period, slightly down from HKD 12,614,000 in the previous year[47] - Other expenses decreased by approximately 54.8% from HKD 11.5 million to HKD 5.2 million, primarily due to reduced operating lease payments and marketing expenses[96] Market and User Data - User data showed an increase in active users, with a total of 1.2 million new users added during the reporting period, marking a 20% increase compared to the previous half[130] - Approximately 78.3% of the group's customers are aged between 26 to 55 years, with about 90.1% being female[86]

2019 / 2020 第一季度報告 MEDIC SKIN MEDICSKIN HOLDINGS LIMITED 密迪斯肌控股有限公司 (於開疊群島註冊成立之有限公司) 股份代號：8307 香港聯合交易所有限公司（「聯交所」）GEM的特色 GEM的定位，乃為中小型公司提供一個上市的市場，此等公司相比起其他在聯交所 上市的公司帶有較高投資風險。有意投資者應了解投資於該等公司的潛在風險，並 應經過審慎周詳的考慮後方作出投資決定。 由於GEM上市公司普遍為中小型公司，在GEM買賣的證券可能會較於主板買賣之 證券承受較大的市場波動風險，同時無法保證在GEM買賣的證券會有高流通量的 市場。 香港交易及結算所有限公司及聯交所對本報告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示概不會就因本報告全部或任何部分內容而產 生或因倚賴該等內容而引致的任何損失承擔任何責任。 本報告由密迪斯肌控股有限公司（「本公司」）董事（「董事」）共同及個別負全責，其 中載有遵照聯交所GEM證券上巿規則（「GEM上巿規則」）所規定有關本公司的資 料。董事在作出一切合理查詢後確認，就彼等所深知及確信，本報告所載資料在各 重大方面均 ...

2018 / 2019 年 報 MEDIC SKIN MEDICSKIN HOLDINGS LIMITED 密迪斯肌控股有限公司 (於開曼群島註冊成立之有限公司) 股份代號：8307 香港聯合交易所有限公司（「聯交所」）GEM的特色 GEM的定位，乃為中小型公司提供一個上市的市場，此等公司相比起其他在聯交所上市的公司帶有較高投資風 險。有意投資者應了解投資於該等公司的潛在風險，並應經過審慎周詳的考慮後方作出投資決定。 由於GEM上市公司普遍為中小型公司，在GEM買賣的證券可能會較於主板買賣之證券承受較大的市場波動風險， 同時無法保證在GEM買賣的證券會有高流通量的市場。 香港交易及結算所有限公司及聯交所對本報告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確 表示概不會就因本報告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 本報告由密迪斯肌控股有限公司（「本公司」）董事（「董事」）共同及個別負全責，其中載有遵照聯交所GEM證券上 巿規則（「GEM上巿規則」）所規定有關本公司的資料。董事在作出一切合理查詢後確認，就彼等所深知及確信，本 報告所載資料在各重大方面均屬準確完備，且 ...

Financial Performance - Total revenue for the three months ended December 31, 2018, was HKD 13,597,000, a decrease of 6.2% compared to HKD 14,497,000 for the same period in 2017[4] - Total revenue for the nine months ended December 31, 2018, was HKD 38,591,000, down 13.2% from HKD 44,450,000 in the previous year[4] - The company reported a net loss of HKD 3,065,000 for the nine months ended December 31, 2018, compared to a profit of HKD 1,793,000 for the same period in 2017[4] - Basic and diluted loss per share for the nine months ended December 31, 2018, was HKD (0.64), compared to HKD 0.37 for the same period in 2017[4] - The total comprehensive loss for the nine months ended December 31, 2018, was HKD 5,796,000, compared to a total comprehensive income of HKD 1,793,000 for the same period in 2017[4] - Basic and diluted loss per share for the nine months ended December 31, 2018, was HKD (3,065) thousand, compared to a profit of HKD 1,793 thousand for the same period in 2017[21] - Revenue decreased by approximately HKD 5.9 million (or 13.3%) to approximately HKD 38.6 million for the nine months ended December 31, 2018, compared to approximately HKD 44.5 million in the same period last year, mainly due to increased competition leading to a reduction in customer numbers and visit frequency[37] Expenses and Costs - Employee costs for the nine months ended December 31, 2018, were HKD 19,044,000, a decrease of 13.3% from HKD 21,985,000 in the previous year[4] - Other expenses for the nine months ended December 31, 2018, increased to HKD 16,166,000 from HKD 11,393,000, representing a rise of 41.5%[4] - Employee costs decreased by approximately HKD 3.0 million (or 13.6%) to approximately HKD 19.0 million for the nine months ended December 31, 2018, mainly due to a reduction in share-based payments and performance bonuses for doctors[41] - Other expenses increased by approximately HKD 4.8 million (or 42.1%) to approximately HKD 16.2 million for the nine months ended December 31, 2018, primarily due to additional costs related to the opening of the Tsim Sha Tsui center[43] Revenue Breakdown - Revenue from consultation services, prescription and dispensing services, and treatment services for the nine months ended December 31, 2018, were approximately HKD 1.4 million, HKD 13.2 million, and HKD 24.0 million, accounting for about 3.6%, 34.2%, and 62.2% of total revenue respectively[26] - More than 84.3% of the revenue from treatment services is generated from procedures performed by doctors[27] Business Operations - The group operates two "Medicskin" medical skin care centers, one anti-aging center, and one beauty center in prime locations in Hong Kong[26] - The company opened the "Ray Lui Anti-Aging and Health Management Center" in Tsim Sha Tsui on June 9, 2018, offering a range of medical beauty treatments to help clients maintain health and youth[30] - The company acquired a 51% stake in the "MS Medicspa" brand beauty center in Causeway Bay on June 11, 2018, which is expected to enhance market penetration and attract more customers[31] Market Conditions - The decrease in revenue is primarily due to increased competition leading to a reduction in the number of customers served and the frequency of visits[27] - The company anticipates continued high operating costs related to leasing and employee expenses, along with intense industry competition, but maintains a cautiously optimistic outlook for future development[36] - The company welcomes the passage of the Private Healthcare Institutions Ordinance, which is expected to enhance patient safety and consumer rights, ultimately increasing market confidence and expansion[34] Shareholder Information - As of December 31, 2018, Topline holds 274,865,400 shares, representing 56.59% of the issued share capital[51] - 富麒, 丰盛, and Magnolia Wealth each hold 80,000,000 shares, accounting for 16.47% of the issued share capital[51] - The company has a total of 4,000,000 unexercised share options as of December 31, 2018, with 1,300,000 options vested and available for issuance[59] Corporate Governance - The audit committee, consisting of three independent non-executive directors, reviewed the unaudited consolidated financial statements for the nine months ended December 31, 2018, and found them compliant with applicable accounting standards[60] - The company has complied with the corporate governance code as per GEM listing rules during the nine months ended December 31, 2018, except for the separation of the roles of chairman and CEO[55] - The company’s board believes that the current structure does not undermine the balance of power and authority between the board and management[55] - The company has not disclosed any direct or indirect business interests that may compete with its operations as of December 31, 2018[54] - The company did not purchase, sell, or redeem any of its listed securities during the nine months ended December 31, 2018[58] New Products - The company launched a new skincare product line "Ray Lui by facematter," which includes four new products, and plans to introduce more varieties to the market[30]